HONG KONG – Tokyo-based Daiichi Sankyo Co. Ltd. has hit its goals in a phase III study testing the use of prasugrel hydrochloride in thrombotic stroke patients.
LONDON – Astrazeneca plc is broadening its antibody-drug conjugate (ADC) relationship with Daiichi Sankyo Co. Ltd. in a potential $6 billion development and commercialization deal. The two companies are to work together on DS-1062, Daiichi’s trophoblast antigen2 (TROP2) ADC, which is in phase I development in multiple tumors that express the cell surface glycoprotein. These include breast cancer and non-small-cell lung cancer (NSCLC), areas of strategic focus for Astrazeneca. The agreement builds on the March 2019 $6.9 billion pact between the two for Enhertu (trastuzumab deruxtecan), the HER2-targeted ADC now on course for blockbuster status, following FDA approval in December 2019 and U.S. launch at the start of the year.
HONG KONG – Tokyo-based Daiichi Sankyo Co. Ltd. has hit its goals in a phase III study testing the use of prasugrel hydrochloride in thrombotic stroke patients.
Thermo Fisher Scientific Inc. is working with Daiichi Sankyo Co. Ltd. to develop a companion diagnostic (CDx) to identify non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who could be eligible for the Tokyo-based company's cancer drug, Enhertu.
The juggernaut that is Daiichi Sankyo Co. Ltd.’s Enhertu continued to roll into this weekend’s American Society of Clinical Oncology virtual meeting, bringing momentum from its December FDA approval for HER2-positive breast cancer, along with fresh data from three new studies in other indications.
The juggernaut that is Daiichi Sankyo Co. Ltd.’s Enhertu continued to roll into this weekend’s American Society of Clinical Oncology virtual meeting, bringing momentum from its December FDA approval for HER2-positive breast cancer, along with fresh data from three new studies in other indications.
HONG KONG – Daiichi Sankyo Co. Ltd., Mitsubishi UFJ Capital Co. Ltd. and Nagoya Institute of Technology have kicked off research on a joint project for a gene therapy that could be applied to the restoration of vision.
SAN DIEGO – At the Biocom 10th Annual Global Life Sciences Partnering Conference, panels of pharma executives highlighted what they're looking for to supplement their pipelines and offered advice that ran the gamut from company formation to the courting process to strategies for partnering pipeline drugs and platforms.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) looked with favor on a bucketload of would-be drugs, issuing positive opinions for the European Commission to consider across a range of indications.
Merus N.V.'s second-quarter earnings report included an important update on phase I MCLA-117, which Jefferies analyst Maury Raycroft said could be a best-in-class "game-changer" for the treatment of acute myeloid leukemia (AML) – a candidate that "alone is a reason to own the stock," in his view.
